SCM
ALLR

Stonepine Capital Management’s Allarity Therapeutics ALLR Stock Holding History

Stonepine Capital Management’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67,289
Closed -$78.7K – 68
2024
Q4 		$78.7K Buy
+67,289
New +$89.2K 0.06% 50

Other funds holding ALLR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Stonepine Capital Management's ALLR Position: Q1 2025 in Review

Stonepine Capital Management sold out of Allarity Therapeutics (ALLR) in Q1 2025, closing a stake of 67,289 shares — an estimated $78.7K sold.

Stonepine Capital Management first reported a position in ALLR in Q4 2024 and held it in 1 quarter. The position peaked at $78.7K in Q4 2024. 9 funds tracked by Wall St. Rank hold ALLR as of Q1 2025.

  • Stonepine Capital Management reported no remaining Allarity Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 67,289 Allarity Therapeutics shares in Q1 2025, an estimated $78.7K.
  • Stonepine Capital Management first reported a position in Allarity Therapeutics in Q4 2024 and held it in 1 quarter.
  • Stonepine Capital Management's Allarity Therapeutics position peaked at $78.7K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2025.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.